preoperative lanreotide treatment in acromegalic patients with macroadenomas

Conditions: Acromegaly

Summary: previous studies addressing preoperative somatostatin analogs (ssa) treatment and subsequent surgical cure rates are conflicting, reporting a benefit, or no difference between groups. and most reported studies were rather small and were made in retrospect, we conducted a prospective, randomized study to investigate whether 4-month preoperative lanreotide treatment would improve the surgical cure rate of newly diagnosed acromegalic patients with macroadenomas. the investigators also aimed to investigate whether there were differences in the incidence of surgical complications, and duration of neurosurgical hospital stay.

acromegaly is a rare disease, caused by a growth hormone (gh)-secreting adenoma and in even more seldom instances (about 1%) due to excessive growth hormone-releasing hormone (ghrh) secretion, usually by a carcinoid tumor of the lung or gastrointestinal tract. the incidence of acromegaly is about 3-4 per 1 million per year and the prevalence is 60-70 per 1 million, without geographical or sex differences. clinical features of acromegaly include acral enlargement, prognathism, jaw malocclusion, arthropathy, carpal tunnel syndrome, hyperhydrosis, sleep apnea, and visceromegaly. transsphenoidal neurosurgery, allowing selective removal of the pituitary adenoma, is the current first treatment for acromegaly in the majority of patients. its effects on gh and insulin-like growth factor i (igf-i) secretion are rapid and operations have a low morbidity and very low mortality. however, surgery for macroadenomas causing acromegaly has a much lower surgical success rate than that for microadenomas. in experienced hands, microadenomas can be expected to be cured in around 90%, whereas with macroadenomas the figure is around 50%. this is particularly the case with tumours that extend into the cavernous sinus where surgical success is \< 50%. medical treatment of acromegaly with somatostatin analogs (ssas) can lead to normalized gh and igf-i levels and relief of symptoms. ssa treatment may cause shrinkage of gh-secreting pituitary adenomas. theoretically, this could improve the likelihood of a radical resection, particularly in macroadenomas. furthermore, it has been suggested that ssa treatment softens the tumor parenchyma and thereby facilitates tumor removal. finally, it has been reported that ssa pretreatment leads to a shortening of postoperative hospital stay. previous studies addressing preoperative ssa treatment and subsequent surgical cure rates are conflicting, reporting a benefit, or no difference between groups. and most reported studies were rather small and were made in retrospect, we conducted a prospective, randomized study to investigate whether 4-month preoperative lanreotide treatment would improve the surgical cure rate of newly diagnosed acromegalic patients with macroadenomas. we also aimed to investigate whether there were differences in the incidence of surgical complications, and duration of neurosurgical hospital stay.

Eligibility criteria:
inclusion criteria: * patients with newly diagnosed acromegaly due to gh-secreting macro-adenomas. * newly diagnosed, previously untreated patients with gh nadir more than 2.5 μg/l during a standard 75-g, 2-h oral glucose tolerance test (ogtt) * pituitary macroadenomas (maximum diameter \>1 cm) verified by a pituitary magnetic resonance imaging (mri) scan * age between 18 and 80 yr. exclusion criteria: * immediate surgery indicated by clinical criteria * pregnancy * contraindications to mri scan * patients judged not suitable to participate in the study for other reasons such as personality disorders and alcohol abuse.

Keywords: acromegaly macroadenomas lanreotide transsphenoidal neurosurgery preoperative